On TRAC with charity donations
Cornish Regulatory Affairs Specialist raises £20,000 through volunteer project
The Camborne, UK-based company, which works with pharmaceutical manufacturers around the world, has donated £22,000 since launching a pioneering project in 2006 in which volunteers across Cornwall raised funds for a charity or community group in return for a 30-minute question and answer session.
The project was launched four years ago to enable pharmaceutical companies to get feedback on Patient Information Leaflets from members of the public, and gave everyone taking part the opportunity to raise money by donating £20 to a nominated charity or group.
More than 50 community groups such as Cornwall Blind Association, St Agnes Football Club, Truro Fencing Club, Cornwall Air Ambulance, and Camborne Bowling Association have all had their funds boosted by the volunteer scheme.
TRAC Director Sarah Trethowan said: ‘When we came up with the idea of running the volunteer project we really didn’t know if it would take off, but are absolutely thrilled that we have been able to donate £22,000 to good causes and community projects in Cornwall.
‘The beauty of the volunteer project was that not only did every person taking part in it raise £20 towards their nominated cause but by taking part they were also helping to improve the way pharmaceutical companies produce information leaflets, making them clearer and easier to understand.’
With the project now coming to an end, TRAC is continuing its charity work by becoming a member of Cornwall Community Foundation’s 100 Club, which has been launched to enable businesses in the county to help fund grassroots organisations and projects.
TRAC recently became the second firm in Cornwall to achieve a Silver Investors in People (IIP) standard. It also took top honours in the Graduate Development Category at the Cornwall Excellence in Business Training Awards 2010.
You may also like
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?
The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Manufacturing
FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing
A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain